

CURRICULUM VITAE ET STUDIORUM

Aldo M. Roccaro

TITOLI DI STUDIO ED ESPERIENZA FORMATIVA

1993	Diploma di Maturità c/o Liceo Scientifico "R. Nuzzi", 58/60, Andria (BA)
1999	Laurea in Medicina e Chirurgia, Università degli Studi di Bari, 110/110 con lode
2004	Conseguimento del titolo di specialista in Oncologia, c/o Università degli Studi di Bari, 50/50 con lode
2004-2008	Research Associate, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
2008	Conseguimento titolo di Dottore di Ricerca; discussione della tesi "Dual targeting of the proteasome regulates survival and homing in Waldenström's Macroglobulinemia"; (Tesi pubblicata: Roccaro et al. <i>Blood</i> , 2008;111:4752-63)
2008-2009	Instructor in Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Luglio '10/Dic. '10	Research Scientist, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Genn. '11/Genn. '16	Senior Research Scientist, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Genn. '16/Dic. '17	Dirigente Medico, Dip. Oncologia Medica, ASST Spedali Civili di Brescia
Dic. 2017-presente	Direttore Progettazione Ricerca Clinica e Studi di Fase I, ASST Spedali Civili di Brescia
Febbraio '17-presente	Consulente esperto, area ematologica, Comitato Etico di Brescia
Settembre 2018	Incarico di insegnamento, Medicina Interna, Università degli Studi di Brescia

PREMI E RICONOSCIMENTI

2016	Premio "Fondazione Calabresi" per la ricerca traslazionale, Milano
2016	Premio "Fondazione Chianello per la ricerca nel campo dell'oncologia clinica e sperimentale", Università degli Studi di Palermo
2015	Premio Internazionale "Francesca de Luca" per la ricerca sui tumori, Accademia Nazionale dei Lincei, Roma (consegnato dal Capo dello Stato Sergio Mattarella)
2015	Premio Internazionale "Campese Award for Leukemias", Italian Scientists and Scholars of North America Foundation, Italian Embassy, Washington, DC, USA (consegnato dall'Ambasciatore Claudio Bisogniero)
2014	International Waldenström's Macroglobulinemia Foundation Award, Sarasota, FL, USA
2012	"V. Rizzo" Award, Accademia Nazionale dei Lincei, Roma
2012	The American Physician Scientist Association Award, Chicago, IL, USA
2009	The Doctors Cancer Foundation Award, New Rochelle, NY, USA
2009	Claudia Adams Barr Award, Harvard Medical School, Boston, MA, USA
2008-2009-2011-2013-2015	American Society of Hematology (ASH) Achievement Award
2009-2011	European Hematology Association (EHA) Abstract Award
2006	Fondazione Berlucci, "Premio Giovani Ricercatori", Borgonovo di Franciacorta, BS
2004	FIRC/AIRC, "Premio Lionello-Fontana per la ricerca all'Estero"

PROGETTI DI RICERCA FINANZIATI

1. *European Union-Transcan2*, 2018-2021
Ruolo: Principal Investigator, € 432,259
"Single-cell immunophenotypic and transcriptomic profiling for minimally-invasive detection of early multiple myeloma"
2. *Italian Association for Cancer Research (AIRC)*, 2017-2020
Ruolo: Principal Investigator, € 210,000

- “Dissecting clonal architecture in Waldenstrom’s Macroglobulinemia for therapeutic interventions”
3. *European Hematology Association (EHA)*, 2017-2019
Ruolo: Principal Investigator, €160,000
“Dissecting transcriptome aberrations within the tumor clone and the bone marrow microenvironment, in Waldenstrom's Macroglobulinemia and the pre-malignant IgM MGUS Stage”
 4. *International Waldenstrom’s Macroglobulinemia Foundation*, 2013-2015
Ruolo: Principal Investigator, \$160,000
“Further genomic characterization of Waldenstrom’s Macroglobulinemia: unveiling the role of the CXCR4 somatic mutation, a crucial regulator of pathogenesis and important target for therapy”
 5. *Doctors Cancer Foundation*, 2009-2010
Ruolo: Principal Investigator”, \$50,000
“Targeting epigenetic modifications in multiple myeloma”
 6. *Claudia Adams Barr/Harvard Medical School*, 2009-2011
Ruolo: Principal Investigator”, \$240,000
“MicroRNA profiling in multiple myeloma”
 7. *Bristol-Myers-Squibb*, 2011-2012
Ruolo: Principal Investigator, \$25,000
“The effect of MDX-1338 on the cell-trafficking and homing of multiple myeloma cells into an out of the bone marrow”
 8. *Health Research Board (HRB) Ireland*, 2013-2014
Ruolo: Principal Investigator, €50,000
“A translational research program in multiple myeloma”
 9. *National Institute of Health/National Cancer Institute (NIH/NCI)_R01*, 2011-2016
Ruolo: Senior Scientist, \$2,168,750
“The role of miRNA-15a and -16-1 in Multiple Myeloma”
 10. *The Leukemia&Lymphoma Society*, 2012-2015
Ruolo: Senior Scientist, \$504,045
“Targeting Hypoxic and Metabolic pathways in Multiple Myeloma”
 11. *Multiple Myeloma Research Foundation*, 2013-2016
Ruolo: Senior Scientist, \$247,500
“Chromatin, Writer, Reader and Erasers in Multiple Myeloma”

ABILITAZIONI SCIENTIFICHE NAZIONALI, MIUR

Conseguimento dell’abilitazione scientifica nazionale, professore prima fascia nei settori:

06/B1-Medicina Interna

06/D3-Malattie del Sangue, Oncologia e Reumatologia

06/A2-Patologia Generale e Patologia Clinica

05/F1-Biologia Applicata

05/E2-Biologia Molecolare

05/E3-Biochimica Clinica e Biologia Molecolare Clinica

MEMBRO SOCIETA’ SCIENTIFICHE

2000-2004 Società Italiana di Medicina Interna

2007- American Society of Hematology (ASH)

2009- European Hematology Association (EHA)

2014- American Association for Cancer Research (AACR)

2016- International Myeloma Society (IMS)

MEMBRO EDITORIAL BOARD

Editorial Board Member

Advances in Hematology; The Scientific World Journal; Translational Medicine Reports

REVISORE AD-HOC PER RIVISTE SCIENTIFICHE PEER-REVIEWED

The Lancet Haematology; Blood; Cancer Research; Clinical Cancer Research; Leukemia; Haematologica; Blood Cancer Journal; PLoS One; British Journal of Haematology; Oncotarget; Neoplasia; Clinical Experimental Medicine; Cancer; Journal of Cellular Biochemistry; Advances in Hematology; Clinical Lymphoma, Myeloma & Leukemia; Annals of Hematology; Expert Opinion On Biological Therapy; Clinical and Experimental Metastasis; Journal of Translational Medicine; European Journal of Haematology

REVISORE PER GRANT INTERNAZIONALI

Alberta Cancer Board, Alberta, Canada; Cancer Research UK Project Grant; Ministero della Salute, Roma; Hungarian Scientific Research Fund (OTKA); Leukemia & Lymphoma Research; Czech Science Foundation; FWF Austrian Science Research Fund; Fonds de Recherche du Quebec

SEMINARI SU INVITO, CONFERENZE SCIENTIFICHE NAZIONALI ED INTERNAZIONALI (selezionate)

- ✓ Harvard Medical School, Boston, MA, USA
- ✓ European Multiple Myeloma Academy
- ✓ University of Pecs, Hungary
- ✓ 77th Japanese Society of Hematology Meeting, Kanazawa, Japan
- ✓ Multiple Myeloma and Related Malignancies
1st, 2nd, 3rd, 4th Editions
- ✓ International Workshop on Waldenström's Macroglobulinemia
3rd, 4th, 5th, 6th, 7th, 8th Editions
- ✓ European Hematology Association 23rd Annual Meeting
- ✓ European School of Hematology
- ✓ Genomics Research
2013, 2014 Editions
- ✓ 3rd Epigenetic World Congress
- ✓ RNAi and miRNA World Congress
- ✓ 4th International microRNAs Europe Meeting
- ✓ Joint Meeting Spanish Hematology and Hemotherapy Society/SHHS – Dana Farber (Pre- Congress Meeting 2016 of the LVIII National Meeting SEHH)
- ✓ ASST Spedali Civili di Brescia
- ✓ Università degli Studi di Bari
- ✓ Università degli Studi di Brescia
- ✓ Università degli Studi di Padova
- ✓ Università degli Studi di Palermo
- ✓ Società Italiana di Ematologia Sperimentale
- ✓ Ospedale Niguarda
- ✓ Grandangolo in Ematologia

PRESENTAZIONI ORALI SELEZIONATE IN OCCASIONE DI CONFERENZE SCIENTIFICHE INTERNAZIONALI

- ✓ 2016: 58th American Society of Hematology (ASH) Meeting, San Diego, CA, USA
- ✓ 2015: 57th American Society of Hematology (ASH) Meeting, Orlando, FL, USA
- ✓ 2015: 20th Congress European Haematology Association, Vienna, Austria
- ✓ 2014: 19th Congress European Haematology Association, Milan, Italy
- ✓ 2014: 19th Congress European Haematology Association, Milan, Italy
- ✓ 2013: 55th American Society of Hematology (ASH) Meeting, New Orleans, LA, USA
- ✓ 2013: 18th Congress European Haematology Association, Stockholm, Sweden
- ✓ 2012: 54th American Society of Hematology (ASH) Meeting, Atlanta, GA, USA
- ✓ 2012: International Bone Marrow and Mineral Society Meeting, Lyon, France
- ✓ 2012: 8th American and Physician Scientist Association, Chicago, IL, USA
- ✓ 2011: 53rd American Society of Hematology (ASH) Meeting, San Diego, CA, USA
- ✓ 2011: 53rd American Society of Hematology (ASH) Meeting, San Diego, CA, USA
- ✓ 2012: 17th Congress European Haematology Association, Amsterdam, NL

- ✓ 2011: 6th Congress of the European Hematology Association, London, UK
- ✓ 2010: 15th Congress of the European Hematology Association, Barcelona, Spain
- ✓ 2010: 15th Congress of the European Hematology Association, Barcelona, Spain
- ✓ 2010: 15th Congress of the European Hematology Association, Barcelona, Spain
- ✓ 2008: 50th American Society of Hematology (ASH) Meeting, San Francisco, CA, USA

CITATION REPORT

Cumulative impact factor (IF): 1073,792

IF medio: 8.45

H-Index: Google Scholar, 52 - Scopus, 45

Citations: 7886

PUBBLICAZIONI IN EXTENSO (selezionate/127)

1. Kawano Y, Zavidij O, Park J, Moschetta M, Kokubun K, Mouhieddine TH, Manier S, Mishima Y, Murakami N, Bustoros M, Pistofidis RS, Reidy M, Shen YJ, Rahmat M, Lukyanchykov P, Karreci ES, Tsukamoto S, Shi J, Takagi S, Huynh D, Sacco A, Tai YT, Chesi M, Bergsagel PL, **ROCCARO AM**, Azzi J, Ghobrial IM. Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression. *J Clin Invest*. 2018;128:2487-2499. **IF: 12.35**
2. Takagi S, Tsukamoto S, Park J, Johnson KE, Kawano Y, Moschetta M, Liu CJ, Mishima Y, Kokubun K, Manier S, Salem KZ, Huynh D, Sacco A, Forward J, **ROCCARO AM**, Battinelli EM, Ghobrial IM. Platelets Enhance Multiple Myeloma Progression via IL-1 β Upregulation. *Clin Cancer Res*. 2018;24:2430-2439. **IF: 10.199**
3. Tsukamoto S, Løvendorf MB, Park J, Salem KZ, Reagan MR, Manier S, Zavidij O, Rahmat M, Huynh D, Takagi S, Kawano Y, Kokubun K, Thruue CA, Nagano K, Petri A, **ROCCARO AM**, Capelletti M, Baron R, Kauppinen S, Ghobrial IM. Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. *Leukemia*. 2018 Jun 20. doi: 10.1038/s41375-018-0161-6. **IF: 10.023**
4. Sacco A, Kawano Y, Moschetta M, Zavidij O, Huynh D, Reagan M, Mishima Y, Manier S, Park J, Morgan E, Takagi S, Wong KK, Carrasco R, Ghobrial IM, **ROCCARO AM**. A novel in vivo model for studying conditional dual loss of BLIMP-1 and p53 in B-cells, leading to tumor transformation. *Am J Hematol*. 2017 May 5. doi: 10.1002/ajh.24778 **IF: 5.303**
5. Sacco A, Fenotti A, Affò L, Bazzana S, Russo D, Presta M, Malagola M, Anastasia A, Motta M, Patterson CJ, Rossi G, Imberti L, Treon SP, Ghobrial IM, **ROCCARO AM**. The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. *Oncotarget*. 2017 Mar 11. doi: 10.18632/oncotarget.16130 **IF: 5.168**
6. Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Lakshmi Bandi R, Amodio N, Xu Y, Szalat R, Gulla A, Samur MK, **ROCCARO A**, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. *Blood*. 2017;129:2233-2245. **IF: 15.132**
7. Glavey SV, Naba A, Manier S, Clauser K, Tahri S, Park J, Reagan MR, Moschetta M, Mishima Y, Gambella M, Rocci A, Sacco A, O'Dwyer ME, Asara JM, Palumbo A, **ROCCARO AM**,* Hynes RO,* Ghobrial IM.* (*Co-LAST AUTHORS). Proteomic characterization of human multiple myeloma bone marrow extracellular matrix. *Leukemia*. 2017 Mar 27. doi: 10.1038/leu.2017.102. **IF: 10.023**
8. Kurdi AT, Glavey SV, Bezman NA, Jhatakia A, Guerriero JL, Manier S, Moschetta M, Mishima Y, **ROCCARO AM**, Detappe A, Liu CJ, Sacco A, Huynh D, Tai YT, Robbins MD, Azzi J, Ghobrial IM. Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. *Mol Cancer Ther*. 2018;17:1454-1463. **IF: 5.365**
9. Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, **ROCCARO AM**, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. *Cell Rep*. 2017;19:218-224. **IF: 8.24**

10. Moschetta M, Kawano Y, Sacco A, Belotti A, Ribolla R, Chiarini M, Giustini V, Bertoli D, Sottini A, Valotti M, Ghidini C, Serana F, Malagola M, Imberti L, Russo D, Montanelli A, Rossi G, Reagan MR, Maiso P, Paiva B, Ghobrial IM, **ROCCARO AM**. Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. *Curr Osteoporos Rep*. 2017;15:499-506. **IF: 3.726**
11. Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, Campigotto F, Salem KZ, Huynh D, Glavey SV, Rivotto B, Sacco A, **ROCCARO AM**, Bouyssou J, Minvielle S, Moreau P, Facon T, Leleu X, Weller E, Trippa L, Ghobrial IM. Prognostic role of circulating exosomal miRNAs in multiple myeloma. *Blood*. 2017 Feb 17. pii: blood-2016-09-742296. **IF: 15.132**
12. **ROCCARO AM,*** Sacco A, Shi J, Chiarini M, Perilla-Glen A, Manier S, Glavey S, Aljawai Y, Mishima Y, Kawano Y, Moschetta M, Correll M, Improgo MR, Brown JR, Imberti L, Rossi G, Castillo JJ, Treon SP, Freedman ML, Van Allen EM, Hide W, Hiller E, Rainville I, Ghobrial IM*. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. (*Co-last and Co-corresponding Authors). *Blood*. 2016;127:2598-606. **IF: 15.132**
13. Manier S, Powers JT, Sacco A, Glavey SV, Huynh D, Reagan MR, Salem KZ, Moschetta M, Shi J, Mishima Y, Roche-Lestienne C, Leleu X, **ROCCARO AM**, Daley GQ, Ghobrial IM. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. *Leukemia*. 2016 Nov 11. doi: 10.1038/leu.2016.296. **IF: 10.023**
14. Bertoli D, Re A, Chiarini M, Sottini A, Serana F, Giustini V, **ROCCARO AM**, Cattaneo C, Caimi L, Rossi G, Imberti L. B- and T-lymphocyte number and function in HIV+/HIV- lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation. *Sci Rep*. 2016 Dec 1;6:37995. doi: 10.1038/srep37995. **IF: 5.228**
15. Manier S, Kawano Y, Bianchi G, **ROCCARO AM**, Ghobrial IM. Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. *Curr Opin Hematol*. 2016 Jul;23(4):426-33. **IF: 2.821**
16. Moschetta M, Mishima Y, Kawano Y, Manier S, Paiva B, Palomera L, Aljawai Y, Calcinotto A, Unitt C, Sahin I, Sacco A, Glavey S, Shi J, Reagan MR, Prosper F, Bellone M, Chesi M, Bergsagel LP, Vacca A, **ROCCARO AM,*** Ghobrial IM.* (*Co-last Senior Authors; Co-last Corresponding Authors). Targeting vasculogenesis to prevent progression in multiple myeloma. *Leukemia*. 2016 Feb 3. doi: 10.1038/leu.2016.3. **IF: 10.023**
17. Sacco A,* **ROCCARO AM,*** (*Co-first Author) Ma D, Shi J, Mishima Y, Moschetta M, Chiarini M, Munshi N, Handin RI, Ghobrial IM. Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. *Cancer Res*. 2016 Jan 15;76(2):463-71. **IF: 9.13**
18. **ROCCARO AM**, Mishima Y, Sacco A, Moschetta M, Shi J, Zhang Y, Reagan MR, Huynh D, Kawano Y, Sahin I, Chiarini M, Manier S, Cea M, Aljawai Y, Glavey S, Morgan E, Pan C, Michor F, Cardarelli P, Kuhne M, Ghobrial IM. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal transition-like transcriptional activation. *Cell Reports*. 2015, pii:S2211-1247(15)00685-3. **IF: 8.24**
19. Ghobrial IM, Redd R, Armand P, Boswell E, Chuma S, Huynh D, Sacco A, **ROCCARO A**, Noonan K, Leblebjian H, Warren D, Henrick P, Castillo JJ, Richardson PG, Matous J, Weller E, Treon SP. Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenström Macroglobulinemia. *Leukemia*. 2015 Jul 3. doi: 10.1038/leu.2015.164. **IF: 10.023**
20. Maiso P, Huynh D, Moschetta M, Sacco A, Aljawai Y, Mishima Y, Asara JM, **ROCCARO AM**, Kimmelman AC, Ghobrial IM. Metabolic signature identifies novel targets for drug resistance in Multiple Myeloma. *Cancer Res*. 2015 Mar 13. pii: canres.3400.2014. **IF: 9.13**
21. Kawano Y, Moschetta M, Manier S, Glavey S, Gorgun G, **ROCCARO AM**, Anderson KC, Ghobrial IM. The bone marrow microenvironment in multiple myeloma. *Immunol Reviews*. 2015;263:160-172. **IF: 9.217**
22. Bouyssou JMC, Ghobrial IM, **ROCCARO AM**. Targeting SDF-1 in multiple myeloma tumor microenvironment. *Cancer Letter*. 2015 Nov 30. pii:S0304-3835(15)00709-0. **IF: 6.491**
23. Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, **ROCCARO AM**, Varga C, Mitsiades CS, Paba-Prada C, Schlossman R, Munshi N, Anderson KC, Richardson PP, Weller E, Ghobrial IM. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. *Br J Haematol*. 2015 Apr 1. doi: 10.1111/bjh.13383. **IF: 5.128**

24. Wang W, Corrigan-Cummins M, Barber EA, Saleh LM, Zingone A, Ghafoor RC, Zhang Y, Kurlander RJ, Korde N, **ROCCARO AM**, Ghobrial IM, Landgren O, Calvo KR. Aberrant levels of miRNAs in bone marrow microenvironment and peripheral blood of myeloma patients and disease progression. *J Mol Diagn.* 2015;17:669-678. **IF: 4.88**
25. Glavey SV, Huynh D, Reagan MR, Manier S, Moschetta M, Kawano Y, **ROCCARO AM**, Ghobrial IM, Joshi L, O'Dwyer ME. The cancer glycome: Carbohydrates as mediators of metastasis. *Blood Rev.* 2015 Jan 23. pii: S0268-960X(15)00005-3. doi: 10.1016/j.blre.2015.01.003. **IF: 6.6**
26. Banwait R, Aljawai Y, Cappuccio J, McDiarmid S, Morgan EA, Leblebjian H, **ROCCARO AM**, Laubach J, Castillo JJ, Paba-Prada C, Treon S, Redd R, Weller E, Ghobrial IM. Extramedullary Waldenstrom Macroglobulinemia. *Am J Hematol*, 2015;90(2):100-4. **IF: 5.303**
27. **ROCCARO AM**, Sacco A, Purschke WG, Moschetta M, Buchner K, Maasch C, Zboralski D, Zöllner S, Vonhoff S, Mishima Y, Maiso P, Reagan MR, Lonardi S, Ungari M, Facchetti F, Eulberg D, Kruschinski A, Vater A, Rossi G, Klussmann S, Ghobrial IM. SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy. *Cell Reports.* 2014;9:118-28. **IF: 8.24**
28. Zhang Y, Moschetta M, Huynh D, Tai YT, Zhang Y, Zhang W, Mishima Y, Ring JE, Tam WF, Xu Q, Maiso P, Reagan M, Sahin I, Sacco A, Manier S, Aljawai Y, Glavey S, Munshi NC, Anderson KC, Pachter J, **ROCCARO AM,*** Ghobrial IM.* (Co-Last Senior Authors). Pyk2 promotes tumor progression in multiple myeloma. *Blood.* 2014; 124:2675-86. **IF: 15.132**
29. Reagan MR, Mishima Y, Glavey SV, Zhang Y, Manier S, Lu ZN, Memarzadeh M, Zhang Y, Sacco A, Aljawai Y, Shi J, Tai YT, Ready JE, Kaplan DL, **ROCCARO AM**, Ghobrial IM. Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. *Blood*, 2014;124:3250-3259. **IF: 15.132**
30. Azab AK, Sahin I, Moschetta M, Mishima Y, Burwick N, Zimmermann J, Romagnoli B, Patel K, Chevalier E, **ROCCARO AM**, Ghobrial IM. CXCR7-dependent angiogenic mononuclear cells trafficking regulates tumor progression in multiple myeloma. *Blood*, 2014;124:1905-1914. **IF: 15.132**
31. Glavey SV, Manier S, Natoni A, Sacco A, Moschetta M, Reagan MR, Murillo LS, Sahin I, Wu P, Mishima Y, Zhang Y, Zhang W, Zhang Y, Morgan G, Joshi L, **ROCCARO AM**, Ghobrial IM, O'Dwyer ME. The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. *Blood.* 2014;124:1765-76. **IF: 15.132**
32. Zhang W, Wang YE, Zhang Y, Leleu X, Reagan M, Zhang Y, Mishima Y, Glavey S, Manier S, Sacco A, Jiang B, **ROCCARO AM,*** Ghobrial IM.* (*Co-Last Senior Authors). Global epigenetic regulation of microRNAs in multiple myeloma. *PLoS One.* 2014;e110973. **IF: 4.09**
33. Sahin I, Azab F, Mishima Y, Moschetta M, Tsang B, Glavey SV, Manier S, Zhang Y, Sacco A, **ROCCARO AM**, Azab AK, Ghobrial IM. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib. *Am J Hematol.* 2014;89:1030-6. **IF: 5.303**
34. Swami A, Reagan MR, Basto P, Mishima Y, Kamaly N, Glavey S, Zhang S, Moschetta M, Seevaratnam D, Zhang Y, Liu J, Memarzadeh M, Wu J, Manier S, Shi J, Bertrand N, Lu ZN, Nagano K, Baron R, Sacco A, **ROCCARO AM**, Farokhzad OC, Ghobrial IM. Engineered nanomedicine for myeloma and bone microenvironment targeting. *Proc Natl Acad Sci U S A*, 2014;111:10287-10292. **IF: 9.504**
35. **ROCCARO AM**, Sacco A, Jimenez C, Maiso P, Moschetta M, Mishima Y, Aljawai Y, Sahin I, Kuhne M, Cardarelli P, Cohen L, San Miguel JF, Garcia-Sanz R, Ghobrial IM. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. *Blood.* 2014;123:4120-4131. **IF: 15.132**
36. Moschetta M, Mishima Y, Sahin I, Manier S, Glavey S, Vacca A,, **ROCCARO AM**, Ghobrial IM. Role of endothelial progenitor cells in cancer progression. *Biochim Biophys Acta.* 2014 Apr 4. pii: S0304-419X(14)00026-2. **IF: 8.901**
37. Bouyssou JM, Manier S, Huynh D, Issa S, **ROCCARO AM**, Ghobrial IM. Regulation of microRNAs in cancer metastasis. *Biochim Biophys Acta.* 2014 Feb 22;1845(2):255-265. **IF: 8.901**
38. Sahin I, Moschetta M, Mishima Y, Glavey SV, Tsang B, Azab F, Manier S, Zhang Y, Maiso P, Sacco A, Azab AK, **ROCCARO AM**, Ghobrial IM. Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination. *Blood Cancer J.* 2014 Apr 25;4:e204. doi: 10.1038/bcj.2014.24. **IF: 8.125**

39. Moschetta M, Basile A, Ferrucci A, Frassanito MA, Rao L, Ria R, Solimando AG, Giuliani N, Boccarelli A, Fumarola F, Coluccia M, Rossini B, Ruggieri S, Nico B, Maiorano E, Ribatti D, **ROCCARO AM**, Vacca A. Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma. *Clin Cancer Res.* 2013;19:4371-4382. **IF: 10.199**
40. **ROCCARO AM**, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM. Bone marrow mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. *J Clin Invest.* 2013;123:4:1542-1554. **IF: 12.35**
41. Liu Y, Quang P, Braggio E, Ngo H, Badalian-Very G, Flores L, Zhang Y, Sacco A, Maiso P, Azab AK, Azab F, Carrasco R, Rollins BJ, **ROCCARO AM**, Ghobrial IM. Novel Tumor Suppressor Function of Glucocorticoid-Induced TNF Receptor GITR in Multiple Myeloma. *PLoS One.* 2013 Jun 13;8(6):e66982. **IF: 4.09**
42. Sacco A, Zhang Y, Maiso P, Manier S, Rossi G, Treon SP, Ghobrial IM, **ROCCARO AM**. microRNA aberrations in Waldenström macroglobulinemia. *Clin Lymph Myel Leuk.* 2013;13:205-7. **IF: 2.308**
43. **ROCCARO AM**, Sacco A, Jia X, Banwait R, Maiso P, Azab F, Flores L, Manier S, Azab AK, Ghobrial IM. Mechanisms of activity of the TORC1 inhibitor everolimus in Waldenström's Macroglobulinemia. *Clin Cancer Res.* 2012;18:6609-6622. **IF: 10.199**
44. Manier S, Sacco A, Leleu X, Ghobrial IM, **ROCCARO AM**. Bone marrow microenvironment in Multiple Myeloma progression. *J Biomed Biotech.* 2012; doi:10.1155/2012/157496. **IF: 3.169**
45. Zhang Y, **ROCCARO AM**, Rombaoa C, Flores L, Obad S, Fernandes SM, Sacco A, Liu Y, Ngo H, Quang P, Azab AK, Azab F, Maiso P, Reagan M, Brown JR, Thai TH, Kauppinen S, Ghobrial IM. LNA-mediated anti-microRNA-155 silencing in low grade B- cell lymphomas. *Blood* 2012;120:1678-1686. **IF: 15.132**
46. Blotta S, Jakubikova J, Calimeri T, **ROCCARO AM**, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC. Canonical and non canonical Hedgehog pathway in the pathogenesis of Multiple Myeloma. (CB-17 SCID mice). *Blood* 2012;120:5002-5013. **IF: 15.132**
47. Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, **Roccaro AM**, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC. Targeting NAD⁺ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition. *Blood.* 2012;120:3519-29. **IF: 15.132**
48. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart CP, **ROCCARO AM**, Sacco A, Ngo HT, Lin CP, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. *Blood.* 2012;119:5782-94. **IF: 15.132**
49. Azab AK, Quang P, Azab F, Pitsillides C, Thompson B, Chonghaile T, Patton JT, Maiso P, Monroe V, Sacco A, Ngo HT, Flores LM, Lin CP, Magnani JL, Kung AL, Letai A, Carrasco R, **ROCCARO AM**, Ghobrial IM. P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. *Blood.* 2012;119:1468-78. **IF: 15.132**
50. Azab F, Azab AK, Maiso P, Calimeri T, Flores L, Liu Y, Quang P, **ROCCARO AM**, Sacco A, Ngo HT, Zhang Y, Morgan BL, Carrasco RD, Ghobrial IM. Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenström's macroglobulinemia. *Clin Cancer Res.* 2012;18:91-104. **IF: 10.1999**
51. Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, Azab F, Quang P, Rodig SJ, Lin CP, **ROCCARO AM**, Rommel C, Ghobrial IM. Defining the role of TORC1/2 in multiple myeloma. *Blood.* 2011;118:6860-70. **IF: 15.132**
52. Sacco A, Aujay M, Morgan B, Azab AK, Maiso P, Liu Y, Zhang Y, Azab F, Ngo HT, Issa GC, Quang P, **ROCCARO AM***, Ghobrial IM* (*Co-Last Authors; *Corresponding Author). Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to anti-tumor activity in Waldenström's macroglobulinemia. *Clin Cancer Res.* 2011;17:1753-64. **IF: 10.199**
53. Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, **ROCCARO AM**, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG. Weekly bortezomib in combination

- with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. *The Lancet Oncology* 2011; 12:263-72. **IF: 36.418**
54. Azab AK, Azab F, Quang P, Maiso P, Sacco A, Ngo HT, Liu Y, Zhang Y, Morgan BL, **ROCCARO AM**, Ghobrial IM. FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. *Clin Cancer Res.* 2011;17:4389-99. **IF: 10.199**
 55. Sacco A, Ghobrial IM, **ROCCARO AM**. Anti-Angiogenic Therapies in the Treatment of Waldenstrom's Macroglobulinemia. *Current cancer drug targets.* 2011; 11:1025-9. **IF: 2.626**
 56. Calvo KR, Landgren O, **ROCCARO AM**, Ghobrial IM. Role of microRNAs from MGUS to multiple myeloma. *Semin Oncol*,2011;48:39-45. **IF: 4.942**
 57. Sacco A, Maiso P, Azab A, Azab F, Zhang Y, Liu Y, Ngo HT, Morgan B, Quang P, Issa G, Ghobrial IM, **ROCCARO AM**. Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis. *Clin Lymphoma Myeloma Leuk.* 2011;11:109-11. **IF: 2.308**
 58. Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa G, **ROCCARO AM**. The bone marrow niche in Waldenström's macroglobulinemia. *Clin Lymphoma Myeloma Leuk.* 2011;11:118-20. **IF: 2.308**
 59. Ghobrial IM, Zhang Y, Liu Y, Ngo H, Azab F, Sacco A, Azab A, Maiso P, Morgan B, Quang P, Issa GC, Leleu X, **ROCCARO A**. Targeting the bone marrow in Waldenström's macroglobulinemia. *Clin Lymphoma Myeloma Leuk.* 2011;11:65-9. **IF: 2.308**
 60. **ROCCARO AM**, Sacco A, Jia X, Azab AK, Maiso P, Ngo HT, Azab F, Runnels J, Quang P, Ghobrial IM. microRNA-dependent modulation of histone acetylation in Waldenstrom Macroglobulinemia. *Blood* 2010;116:1506-14. **IF: 15.132**
 61. **ROCCARO AM**, Sacco A, Aujay M, Ngo HT, Azab AK, Azab F, Quang P, Maiso P, Runnels J, Anderson KC, Demo S, Ghobrial IM. Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom Macroglobulinemia. *Blood.* 2010;115:4051-60. **IF: 15.132**
 62. **ROCCARO AM**, Sacco A, Husu EN, Pitsillides C, Vesole S, Azab AK, Azab F, Melhem M, Ngo HT, Quang P, Maiso P, Runnels J, Liang MC, Wong KK, Lin C, Ghobrial IM. Dual targeting of the PI3K/Akt/mTOR pathway as an anti-tumor strategy in Waldenstrom's Macroglobulinemia. *Blood,* 2010;115:559-69. **IF: 15.132**
 63. Sacco A, **ROCCARO A**, Ghobrial IM. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia. *Oncotarget.* 2010;1:578-82. **IF: 5.168**
 64. Sacco A, Ghobrial IM, **ROCCARO AM**. Epigenetics in Waldenström's macroglobulinemia. *Epigenomics,* 2010;2:691-6. **IF: 4.979**
 65. Sacco A, Issa GC, Zhang Y, Liu Y, Maiso P, Ghobrial IM, **ROCCARO AM**. Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. *J Hematol Oncol.* 2010 Oct 7;3:38. **IF: 7.333**
 66. **ROCCARO AM**, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM. microRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. *Blood.* 2009; 113:6669-80. **IF: 15.132**
 67. **ROCCARO AM**, Sacco A, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, Ghobrial IM. microRNA expression in the biology, prognosis and therapy of Waldenstrom Macroglobulinemia. *Blood,* 2009;113:4391-402. **IF: 15.132**
 68. Ghobrial,* **ROCCARO A**,* (Co-First Authors) Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG.*CO-FIRST AUTHOR Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. *Clin Cancer Res.* 2010;16:1033-41. **IF: 10.199**
 69. Ghobrial IM, Leleu X, Azab AK, Runnels J, Jia X, Ngo H, Melhem M, Azab F, Sacco A, Quang P, Burwick N, Moreau AS, Husu E, Farag M, **ROCCARO A**. Novel therapeutic agents in Waldenström's macroglobulinemia. *Clin Lymphoma Myeloma.* 2009;9:84-6. **IF: 2.308**

70. **ROCCARO AM**, Sacco A, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem M, Moreau AS, Ghobrial IM. Role of proteasome inhibition in Waldenström's macroglobulinemia. *Clin Lymphoma Myeloma*. 2009;9:94-6. **IF: 2.308**
71. Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, **ROCCARO AM**, Ngo HT, Melhem MR, Sacco A, Jia X, Anderson KC, Lin CP, Rollins BJ, Ghobrial IM. Rho-A and Rac-1 GTPases play major and differential roles in SDF1-induced cell adhesion and chemotaxis in multiple myeloma. *Blood*. 2009; 114:619-29. **IF: 15.132**
72. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. *J Clin Oncol*. 2009 ;27:250-5. **IF: 26.303**
73. Ngo HT, Azab AK, Farag M, Jia X, Melhem MM, Runnels J, **ROCCARO AM**, Azab F, Sacco A, Leleu X, Anderson KC, Ghobrial IM. Src Tyrosine Kinase Regulates Adhesion and Chemotaxis in Waldenstrom Macroglobulinemia. *Clin Cancer Res*. 2009; 15:6035-41. **IF: 10.199**
74. Skert C, Damiani D, Michelutti A, Patriarca F, Arpinati M, Fili C, Lucchi P, Malagola M, Bergonzi C, **ROCCARO AM**, Peli A, Ricotta D, Caimi L, Fanin R, Baccarani M, Russo D. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after Allo-SCT: results of a prospective study. *Bone Marrow Transplant*. 2009; 44:729-37. **IF: 4.497**
75. Leleu X, Hunter ZR, Xu L, **ROCCARO AM**, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, Adamia S, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. *Br J Haematol*. 2009;145:59-63. **IF: 5.128**
76. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, **ROCCARO AM**, Ngo HT, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ, Anderson KC, Kung AL, Lin CP, Ghobrial IM. The CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. *Blood*, 2009; 113:4341-51. **IF: 15.132**
77. Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, Adamia S, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, **ROCCARO AM**, Ghobrial IM, Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom Macroglobulinemia. *Blood*, 2009;113:626-34. **IF: 15.132**
78. Stedman J, **ROCCARO AM**, Ghobrial IM. Individualizing treatment for Waldenstrom's Macroglobulinemia. *Expert Rev Hematol* 2009; ;2:473-6. **IF: 2.439**
79. Leleu X, Tamburini J, **ROCCARO AM**, Morel P, Soumerai J, Lévy V, Wemeau M, Balkaran S, Poulain S, Hunter ZR, Ghobrial IM, Treon SP, Leblond V. Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. *Clin Lymphoma Myeloma*. 2009;9:71-3. **IF: 2.308**
80. Laubach JP, Mitsiades CS, **ROCCARO AM**, Ghobrial IM, Anderson KC, Richardson PG. Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenström's Macroglobulinemia. *Leuk Lymphoma*. 2009;50:694-702. **IF: 2.40**
81. Pascal L, Gay J, Willekens C, Wemeau M, Balkaran S, Robu D, **ROCCARO AM**, Morel P, Ghobrial I, Leleu X. Bortezomib and Waldenstrom's macroglobulinemia. *Expert Opin Pharmacother*. 2009;10:909-16. **IF: 3.475**
82. Leleu X, Gay J, **ROCCARO AM**, Moreau AS, Poulain S, Dulery R, Champs BB, Robu D, Ghobrial IM. Update on therapeutic options in Waldenström macroglobulinemia. *Eur J Haematol*. 2009;82:1-12. **IF: 2.595**
83. **ROCCARO AM**, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, Treon SP, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM. Dual targeting of the proteasome regulates survival and homing in Waldenstrom's Macroglobulinemia. *Blood*, 2008;111:4752-63. **IF: 15.132**
84. **ROCCARO AM**, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP. Resveratrol exerts anti-

- proliferative activity and induces apoptosis in Waldenstrom's Macroglobulinemia. *Clin Cancer Res*, 2008;14:1849-1858. **IF: 10.199**
85. Moreau AS, Jia X, Patterson CJ, **ROCCARO AM**, Xu L, Sacco A, O'Connor K, Soumerai J, Ngo HT, Hatjiharissi E, Hunter ZR, Ciccarelli B, Manning R, Ghobrial IM, Leleu X, Treon SP. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. *Br J Haematol*. 2008;142:775-85. **IF: 5.128**
 86. Moreau AS, Sebti Y, Duhamel A, **ROCCARO AM**, Coiteux V, Gastinne T, Le Fric G, Burwick N, Amiot L, Ho AW, Poulain S, Hennache B, Hunter ZR, Dessaint JP, Ghobrial IM, Treon SP, Facon T, Zorn E, Leleu X. Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia. *Eur J Haematol*. 2008;80:503-509. **IF: 2.595**
 87. Leleu X, Eeckhoutte J, Jia X, **ROCCARO AM**, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melhem MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM. Targeting NF- κ B in Waldenstrom macroglobulinemia. *Blood*, 2008;111:5068-5077. **IF: 15.132**
 88. Leleu X, Moreau AS, Weller E, **ROCCARO AM**, Coiteux V, Manning R, Nelson M, Leduc R, Robu D, Dupire S, Hatjiharissi E, Burwick N, Darre S, Hennache B, Treon SP, Facon T, Gertz MA, Ghobrial IM. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom Macroglobulinemia. *Leuk Lymphoma*, 2008;49:1104-1107. **IF: 2.40**
 89. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, Moreau AS, Burwick N, Azab AK, **ROCCARO AM**, Azab F, Sacco A, Farag M, Sackstein R, Ghobrial IM. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom Macroglobulinemia. *Blood*, 2008;112:150-58. **IF: 15.132**
 90. Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, **ROCCARO AM**, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM. Targeting Akt and HSP90 produces synergistic Multiple Myeloma cell cytotoxicity in the bone marrow microenvironment. *Clin Cancer Res*, 2008;14:865-874. **IF: 10.199**
 91. Leleu X, **ROCCARO AM**, Moreau AS, Dupire S, Robu D, Gay J, Hatjiharissi E, Burwick N, Ghobrial IM. Waldenstrom macroglobulinemia. *Cancer Lett*, 2008;18:95-107. **IF: 6.491**
 92. Burwick N, **ROCCARO AM**, Leleu X, Ghobrial IM. Targeted therapies in Waldenström macroglobulinemia. *Curr Opin Investig Drugs*. 2008;9:631-637. **IF: 3.55**
 93. **ROCCARO AM**, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A, Dammacco F, Anderson KC. Bortezomib as an antitumor agent. *Curr pharm biotech* 2007;76:441-8. **IF: 2.14**
 94. Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, Spencer JA, Pitsillides CM, Hatjiharissi E, **ROCCARO AM**, O'Sullivan G, McMillin DW, Moreno D, Kiziltepe T, Carrasco R, Treon SP, Hideshima T, Anderson KC, Lin CP, Ghobrial IM. The Akt pathway regulates survival and homing in Waldenstrom Macroglobulinemia. *Blood*, 2007;110:4417-26. **IF: 15.132**
 95. Treon SP, Hatjiharissi E, Leleu X, Moreau AS, **ROCCARO AM**, Hunter ZR, Soumerai JD, Ciccarelli B, Xu L, Sacco A, Ngo HT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson CJ, Ghobrial I. Novel agents in the treatment of Waldenstrom's macroglobulinemia. *Clin Lymphoma Myeloma*. 2007;7:199-206. **IF: 2.308**
 96. Ribatti D, Nico B, Crivellato E, **ROCCARO AM**, Vacca A. The history of the angiogenic switch concept. *Leukemia*. 2007;21:44-52. **IF: 10.023**
 97. Malagola M, Damiani D, Martinelli G, Michelutti A, Cesana B, Vivo AD, Piccaluga PP, Ottaviani E, Candoni A, Geromin A, Tiribelli M, Fanin R, Testoni N, Lauria F, Bocchia M, Gobbi M, Pierri I, Zaccaria A, Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A, Visani G, Skert C, Bergonzi C, **ROCCARO AM**, Filí C, Baccarani M, Russo D. Case-control study of multidrug resistance phenotype and response to inductiopn treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. *Br J Haematol*. 2006;136:87-95. **IF: 5.128**
 98. **ROCCARO AM**, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC. Bortezomib mediates anti-angiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. *Cancer Res*. 2006;66:184-91. **IF: 9.130**
 99. Yasui H, Hideshima T, Raje N, **ROCCARO AM**, Shiraishi N, Kumar S, Hamasaki M, Ishitsuka K, Tai YT, Podar K, Catley L, Mitsiades CS, Richardson PG, Albert R, Brinkmann V, Chauhan D, Anderson KC.

- FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. *Cancer Res.* 2005;65:7478-7484. **IF: 9.130**
100. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Podar K, Le Gouill S, Shiraishi N, Yasui H, **ROCCARO AM**, Tai YZ, Chauhan D, Fram R, Tamura K, Jain J, Anderson KC. Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. *Oncogene*, 2005;24:5888-589. **IF: 6.854**
 101. Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, Shiraishi N, Yasui H, **ROCCARO AM**, Richardson P, Podar K, Le Gouill S, Chauhan D, Tamura K, Arbiser J, Anderson KC. Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and independent apoptosis. *Blood*. 2005;106:1794-1800. **IF: 15.132**
 102. Raje N, Kumar S, Hideshima T, **ROCCARO AM**, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC. Seliciclib (CYC202 or R-Roscovitin), a small molecule cyclin dependent kinase inhibitor, mediates activity via downregulation of Mcl-1 in multiple myeloma. *Blood*. 2005;106:1042-1047. **IF: 15.132**
 103. Kumar S, Raje N, Hideshima T, Ishitsuka K, **ROCCARO AM**, Shiraishi N, Hamasaki M, Yasui H, Munshi NC, Richardson P, Figg WD, Anderson KC. Antimyeloma activity of two novel N-substituted and tetrafluorinated thalidomide analogs. *Leukemia*. 2005;19:1253-1261. **IF: 10.023**
 104. Yasui H, Hideshima T, Hamasaki M, **ROCCARO AM**, Shiraishi N, Kumar S, Tassone P, Ishitsuka K, Raje N, Tai YT, Podar K, Chauhan D, Leoni LM, Kanekal S, Elliott G, Munshi NC, Anderson KC. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. *Blood*. 2005;106:706-712. **IF: 15.132**
 105. Ribatti D, Crivellato E, **ROCCARO AM**, Ria R, Vacca A. Mast cell contribution to angiogenesis related to tumour progression. *Clin Exp Allergy*. 2004;34:1660-1664. **IF: 5.158**
 106. Ribatti D, Molica S, Vacca A, Nico B, Crivellato E, **ROCCARO AM**, Dammacco F. Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. *Leukemia*, 2003;17:1428-1430. **IF: 10.023**
 107. Ria R, **ROCCARO AM**, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. *Leukemia*, 2003;17:1961-1966. **IF: 10.023**
 108. Ribatti D, Vacca A, **ROCCARO AM**, Crivellato E, Presta M. Erythropoietin as an angiogenic factor. *Eur J Clin Invest*, 2003;33:891-896. **IF: 3.086**
 109. Fanelli M, Sarmiento R, Gattuso D, Carillio G, Capaccetti B, Vacca A, **ROCCARO AM**, Gasparini G. Thalidomide: a new anticancer drug? *Expert Opin Invest Drugs*, 2003;12:1201-1215. **IF: 4.03**
 110. Molica S, Vacca A, Ribatti D, Cuneo A, Cavazzini F, Levato D, Vitelli G, Tucci L, **ROCCARO AM**, Dammacco F. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leucemia. *Blood*, 2002;100:3344-3351. **IF: 15.132**
 111. Vacca A, Ribatti D, **ROCCARO AM**, Frigeri A, Dammacco F. Bone marrow angiogenesis in patients with active multiple myeloma. *Semin. Oncol.*, 2001;28:543-550. **IF: 4.942**

COMMENTARIES RELATIVI A LAVORI PUBBLICATI

1. LATHIA JD. EDITOR'S CHOICE. Protecting the fortress: preventing metastasis by neutralizing niche homing. *Sci Transl Med* 8 October 2014: Vol. 6, Issue 257, p. 257ec172. Commentary related to Roccaro et al. *Cell Reports*. 2014;9:118-28.
2. EFEBERA YA. It is time to move forward with Waldenstrom! *Blood* 2014;123:4007-4008. Commentary related to Roccaro et al. *Blood*. 2014;123:4120-31.
3. BOISE LH. Aiming at WM with both barrels blocked. *Blood* 2010;115:4007-4008. Commentary related to Roccaro et al. *Blood*. 2010;115:4051-60.

CAPITOLI DI LIBRI

1. Plasma Cell Dyscrasias. Book. Springer. Editors: **ROCCARO AM**, Ghobrial IM.
2. Glavey S, Manier S, Sacco A, Salem K, Kawano Y, Bouyssou J, Ghobrial IM, **ROCCARO AM**. Epigenetics in multiple myeloma. In: Plasma Cell Dyscrasias. 2016. Springer. (Editors: AM Roccaro, IM Ghobrial).

3. Manier S, Salem K, Glavey S, **ROCCARO AM**, Ghobrial IM. Genomic aberrations in multiple myeloma. In: Plasma Cell Dyscrasias. 2016. Springer. (Editors: AM Roccaro, IM Ghobrial).
4. Sacco A, Moschetta M, Manier S, Rossi G, Ghobrial IM, **ROCCARO AM**. Molecular pathways in growth and survival: Epigenomics. In: Waldenstrom's Macroglobulinemia. 2016. Springer. (Editors: V. Leblond, S. Treon, M. Dimopoulos).
5. Kastritis E, **ROCCARO A**, Migous M, Ghobrial IM. The Bone Marrow Microenvironment and Tumor Cells Interactions in Waldenström's Macroglobulinemia. In: Waldenstrom's Macroglobulinemia. 2016 (Editors: V. Leblond, S. Treon, M. Dimopoulos). Springer.
6. **ROCCARO AM**, Bianchi G, Ghobrial IM, Anderson KC Multiple Myeloma. Hematology-Oncology Therapy Guidelines. NCI. 2014; McGraw-Hill. Book Chapter.
7. **ROCCARO AM**, Ghobrial IM. microRNA aberrations and their role in supporting hematologic malignancies. Editorial in MicroRNA, 2013;Vol.2; n.3. Bentham Science Publishers.
8. Glavey S, Manier S, Sacco A, Rossi G, Ghobrial IM, **ROCCARO AM**. The role of miRNAs in plasma cells dyscrasias. MicroRNA, 2013; 2014;2(3):165-73. Bentham Science Publishers.
9. Ghobrial IM **AM ROCCARO**, Leleu X. Bortezomib in Waldenstrom's Macroglobulinemia. In: Bortezomib in the treatment of multiple myeloma. Editors: Drs. IM Ghobrial, PG Richardson, KC Anderson. Springer. 2011.
10. **ROCCARO AM**, Vacca A, Rossi G, Ghobrial IM. The multiple myeloma bone marrow microenvironment. Editors: Drs. K. Podar, KC Anderson. 2011. Bentham Science Publishers. E-Book.
11. Ghobrial IM, Leleu X, **ROCCARO AM**, Burwick N, Treon SP. Advances in the understanding and treatment of Waldenström Macroglobulinemia. 2010. Multiple Myeloma State of the Art Second Edition. Editors: Drs. PG Richardson, KC Anderson. Remedica
12. **ROCCARO AM**, IM GHOBRIAL. Novel Antiangiogenic Molecules in Multiple Myeloma. Recent Advances in Angiogenesis and Anti-angiogenesis. Editor: Dr. D. Ribatti. 2009;127-133. Bentham Publishers.
13. Vacca A, **ROCCARO AM**, Ribatti D, Scavelli C, Dammacco F. Angiogenesis and anti-angiogenesis. Editor: F. Morabito. Il Mieloma Multiplo. 2003;311-329, PAVIA: Selecta Medica.
14. Vacca A., Rossini B, **ROCCARO AM**, Dammacco F. Genomic alterations of plasma cells and microenvironment. 2005; 181-186, BOLOGNA: Società Editrice Esculapio.
15. Vacca A, **ROCCARO AM**, Scavelli C, Ribatti D, Dammacco F. Anti-angiogenic effects of chemoterapeuticals. In: "Seminars in Oncology. Angiogenesis and Neoplasias: clinical relevance and therapeutical implications". 2002. Editor: Molica.
16. Ribatti D, **ROCCARO AM**, De Falco G, Vacca A. Methodologies for studying angiogenesis. In: "Seminars in Oncology. Angiogenesis and Neoplasias: clinical relevance and therapeutical implications". Editor: Molica.

BREVETTI

- ✓ Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia. Patent number: US8394816 B2
- ✓ Compositions and methods for diagnosis, prognosis and treatment of hematological malignancies. Patent number:WO2014071205 A1

ALTRO

- ✓ Traduzione dall'Inglese all'Italiano del testo-atlante "*Netter, Clinical Anatomy*"
- ✓ ASH Abstract Reviewer (56th ASH meeting, San Francisco, CA, USA, 2014)
- ✓ ASH Education Program Real Time Peer Reviewer (56th ASH meeting, San Francisco, CA, USA, 2014)
- ✓ ASH Abstract Reviewer (51st ASH Meeting, New Orleans, LA, USA, 2009)
- ✓ EHA Abstract Reviewer (21st EHA Congress, Copenhagen, June 2016)
- ✓ Consulente esperto per l'area ematologica, Comitato Etico di Brescia